Please login to the form below

Not currently logged in

NICE set to block post-Velcade use of Revlimid

Celgene Revlimid lenalidomide

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

Pfizer acquires Baxter Men C and encephalitis vaccines for $635m

Pfizer headquartersSnaps up marketed vaccines and part of Baxter's Austrian manufacturing plant

Amgen cuts workforce and facilities despite profit leap

Amgen flagUS biopharma plans 12-15 per cent workforce reduction

European licence for BMS/Pfizer's Eliquis in DVT and PE

Pfizer BMS Eliquis apixaban atrial fibrilationAnticoagulant catches up with Bayer's Xarelto and Boehringer's Pradaxa

Merck Serono enters anti-PD-1 fray

Merck Serono Geneva HQMoves skin cancer antibody candidate into phase II trials

Roche wins European approval for new leukaemia drug

Roche - Basel, SwitzerlandGazyvaro now available for use in treatment of blood cancer in the EU

J&J’s Imbruvica wins new cancer indication

FDA headquarters White OakFDA backs drug’s use in chronic lymphocytic leukaemia patients with genetic mutation

Novartis' glaucoma combo cleared in Europe

Novartis buildingSimbrinza approved to treat eye condition

Reckitt Benckiser confirms pharma spin-off plans

Reckitt BenckiserWill separate prescription and consumer health businesses

bms merger time travelThis month in 1989: the creation of Bristol-Myers Squibb

The emergence of a company with a new focus on healthcare and research

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company

Clients who’ve found out how hard we work at keeping their brands performing tend to stay with us. That’s why...

Latest intelligence

Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...
The Chinese diabetes challenge
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential ...